CervoMed Announces Neflamapimod Formulation Advancement
CervoMed has introduced a stable 50 mg tablet formulation to replace a previous capsule, paving the way for a higher, twice-daily dosing regimen. This regulatory and manufacturing progress aims to reduce clinical trial execution risk for the age-related brain disorder treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed